<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367991</url>
  </required_header>
  <id_info>
    <org_study_id>0506000140</org_study_id>
    <secondary_id>0555844T</secondary_id>
    <nct_id>NCT00367991</nct_id>
  </id_info>
  <brief_title>Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a naturally-occurring hormone called erythropoietin
      changes the action of platelets in the blood. Patients with heart attacks are treated with
      medicines to reduce the clotting action of platelets. This study is trying to determine
      whether erythropoietin alters the clotting action of platelets in patients receiving
      anti-platelet medicines. It is important to understand the effects of erythropoietin on
      platelets since preliminary studies in animals suggest that erythropoietin may protect the
      heart from damage during a heart attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-apoptotic effects of erythropoietin in experimental myocardial infarction (MI) and
      ischemia-reperfusion injury suggest potential for therapeutic benefit in patients with acute
      MI. Before the therapeutic potential of recombinant human erythropoietin (rHuEpo) in acute MI
      can be tested in large clinical trials, more information on the effects of short-term rHuEpo
      on platelet function are needed. Accordingly, the current proposal aims to determine the
      effects of rHuEpo (at a dose previously shown not to inhibit the anti-platelet effects of
      aspirin and clopidogrel in healthy subjects) on platelet function and other safety measures
      and measure of infarct size in patients with acute coronary syndromes receiving
      clinically-indicated standard anti-platelet therapy with aspirin, clopidogrel and
      glycoprotein Iib-IIIa inhibitors.

      Specific Aim 1: To determine the effects of intravenous rHuEpo 400 U/kg daily for 3 days vs.
      placebo on in vivo and in vitro platelet function in patients with acute MI undergoing
      percutaneous revascularization.

      Specific Aim 2: To obtain pilot data to estimate the effects of administration of rHuEpo 400
      U/kg daily for 3 days vs. placebo on biochemical markers of myocardial infarction size and
      left ventricular ejection fraction in patients with acute MI undergoing percutaneous
      revascularization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Time</measure>
    <time_frame>Change from Day 3 to Day 10</time_frame>
    <description>An integrated measure of in vivo platelet function and tissue hemostasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet Function Assay Closure Time</measure>
    <time_frame>Change from Day 3 to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Markers of Myocyte Damage</measure>
    <time_frame>Baseline</time_frame>
    <description>Myocyte Damage is represented by Creatine phosphokinase (CPK). CPK is measured in U/L, as scalar measure of the enzyme activity. CPK was measured for clinical indications laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Endothelial Progenitor Cells</measure>
    <time_frame>Day 3 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Markers of Apoptosis</measure>
    <time_frame>Day 1 and Day 10</time_frame>
    <description>Apoptosis is represented by Fas ligand (FasL or CD95L). FasL (CD95L) is measured in pg/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant human erythropoietin 200 U/kg IV daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline volume to match active treatment IV daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human erythropoietin alfa (drug)</intervention_name>
    <description>200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline to match active drug (rHuEpo)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-75 years

          -  Clinical evidence of acute myocardial infarction (MI) with total or sub-total
             occlusion on angiogram

          -  Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow

          -  Ongoing clinically-indicated treatment with aspirin, thienopyridines

        Exclusion Criteria:

          -  Hemodynamic instability/shock or severe congestive heart failure

          -  Time from onset of chest pain to revascularization procedure &gt; 16 hours

          -  Use of intravenous thrombolytic agents for treatment of MI

          -  Known need for additional revascularization procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tang YD, Hasan F, Giordano FJ, Pfau S, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J. 2009 Dec;158(6):941-7. doi: 10.1016/j.ahj.2009.06.032.</citation>
    <PMID>19958860</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <results_first_submitted>August 9, 2011</results_first_submitted>
  <results_first_submitted_qc>August 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2011</results_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet function tests</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rHuEPO</title>
          <description>recombinant human erythropoietin 200 U/kg IV daily for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline volume to match active treatment IV daily for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rHuEPO</title>
          <description>recombinant human erythropoietin 200 U/kg IV daily for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline volume to match active treatment IV daily for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="53" spread="9"/>
                    <measurement group_id="B3" value="56" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Time</title>
        <description>An integrated measure of in vivo platelet function and tissue hemostasis.</description>
        <time_frame>Change from Day 3 to Day 10</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Time</title>
          <description>An integrated measure of in vivo platelet function and tissue hemostasis.</description>
          <population>ITT</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020" lower_limit="960" upper_limit="1110"/>
                    <measurement group_id="O2" value="1020" lower_limit="960" upper_limit="1110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Platelet Function Assay Closure Time</title>
        <time_frame>Change from Day 3 to Day 10</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Function Assay Closure Time</title>
          <population>ITT</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" lower_limit="185" upper_limit="301"/>
                    <measurement group_id="O2" value="281" lower_limit="173" upper_limit="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction</title>
        <time_frame>Day 1 and Day 10</time_frame>
        <population>These data were not collected due to lack of funds.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <population>These data were not collected due to lack of funds.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Markers of Myocyte Damage</title>
        <description>Myocyte Damage is represented by Creatine phosphokinase (CPK). CPK is measured in U/L, as scalar measure of the enzyme activity. CPK was measured for clinical indications laboratory.</description>
        <time_frame>Baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Markers of Myocyte Damage</title>
          <description>Myocyte Damage is represented by Creatine phosphokinase (CPK). CPK is measured in U/L, as scalar measure of the enzyme activity. CPK was measured for clinical indications laboratory.</description>
          <population>ITT</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817" lower_limit="114" upper_limit="2040"/>
                    <measurement group_id="O2" value="652" lower_limit="379" upper_limit="868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Endothelial Progenitor Cells</title>
        <time_frame>Day 3 and Day 10</time_frame>
        <population>Endothelial progenitor cells could not be isolated and are therefore not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Endothelial Progenitor Cells</title>
          <population>Endothelial progenitor cells could not be isolated and are therefore not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Markers of Apoptosis</title>
        <description>Apoptosis is represented by Fas ligand (FasL or CD95L). FasL (CD95L) is measured in pg/mL.</description>
        <time_frame>Day 1 and Day 10</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>normal saline</description>
          </group>
          <group group_id="O2">
            <title>rHuEPO</title>
            <description>recombinant human erythropoietin</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Markers of Apoptosis</title>
          <description>Apoptosis is represented by Fas ligand (FasL or CD95L). FasL (CD95L) is measured in pg/mL.</description>
          <population>ITT</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="12"/>
                    <measurement group_id="O2" value="56" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="18"/>
                    <measurement group_id="O2" value="63" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>rHuEPO</title>
          <description>recombinant human erythropoietin 200 U/kg IV daily for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline volume to match active treatment IV daily for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stuart Katz, MD</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212-263-3946</phone>
      <email>stuart.katz@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

